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Abstract
Predictive markers linking drug efficacy to clinical outcome are a key component in the drug discovery and development
process. In HIV infection, two different measures, viral load decay and phenotypic assays, are used to assess drug efficacy in
vivo and in vitro. For the newly introduced class of integrase inhibitors, a huge discrepancy between these two measures of
efficacy was observed. Hence, a thorough understanding of the relation between these two measures of drug efficacy is
imperative for guiding future drug discovery and development activities in HIV. In this article, we developed a novel viral
dynamics model, which allows for a mechanistic integration of the mode of action of all approved drugs and drugs in late
clinical trials. Subsequently, we established a link between in vivo and in vitro measures of drug efficacy, and extract
important determinants of drug efficacy in vivo. The analysis is based on a new quantity—the reproductive capacity—that
represents in mathematical terms the in vivo analog of the read-out of a phenotypic assay. Our results suggest a drug-class
specific impact of antivirals on the total amount of viral replication. Moreover, we showed that the (drug-)target half life,
dominated by immune-system related clearance processes, is a key characteristic that affects both the emergence of
resistance as well as the in vitro–in vivo correlation of efficacy measures in HIV treatment. We found that protease- and
maturation inhibitors, due to their target half-life, decrease the total amount of viral replication and the emergence of
resistance most efficiently.
Citation: von Kleist M, Menz S, Huisinga W (2010) Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV. PLoS Comput Biol 6(3): e1000720.
doi:10.1371/journal.pcbi.1000720
Editor: Niko Beerenwinkel, ETH Zurich, Switzerland
Received September 2, 2009; Accepted February 23, 2010; Published March 26, 2010
Copyright:  2010 von Kleist et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: MvK and WH acknowledge funding from National University of Ireland and the DFG Research Center Matheon. SM acknowledges financial support by
DFG funding, provided through the Dahlem Research School of Freie Universita ¨t Berlin. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vkleist@zedat.fu-berlin.de
Introduction
Since 1996, human immunodeficiency virus (HIV) infection
is treated with a combination therapy, known as highly active
anti-retroviral therapy (HAART) [1,2], which has substantially
improved the clinical management of HIV [3]. Despite the success
of HAART, eradication of HIV can currently not be achieved
[4,5], most likely due to the persistence of virus in very long lived,
latently infected cells [6,7]. For HIV-infected individuals, life-long
therapy is therefore required to prevent progression to the
acquired immunodeficiency syndrome (AIDS) and death.
During therapy, plasma viral load (HIV RNA per mL blood
plasma) is recommended by the National Institute of Health
as a marker of therapy success [8], whereas measurement of
the CD4 cell count is the most important clinical marker of
disease progression [9]. The in vivo potency of novel antivirals is
usually assessed by viral load decline in small clinical trials of
monotherapy, e.g., [10,11], and later evaluated utilizing the
novel agent in combination with an optimized background
therapy, e.g., [12]. The in vitro potency of antivirals is typically
assessed by using phenotypic/single-round infectivity assays
[13–16], which measure the number of offspring after one round
of virus replication.
Investigation of novel drug targets for the treatment of HIV
infection resulted in the development of new drug classes. In 2003
and 2007, the fusion inhibitor (FI) enfuvirtide [17], the CCR5-
antagonist maraviroc [18] and the integrase inhibitor raltegravir
[19] were approved for the treatment of HIV infection. Many
more drugs are in late clinical development [20]. With the
introduction of new drug classes, in particular integrase inhibitors,
a huge discrepancy between the efficacy measured in vitro, using
phenotypic/single-round infectivity assays, and in vivo, using viral
load decline, was observed [14,21]. Although integrase inhibitors
cause a steep initial decline of plasma viral load [21–26], the in vitro
efficacy is amongst the lowest [14].
Mathematical modelling of viral dynamics has lead to many
insights into the pathogenesis and treatment of HIV. It is a
valuable tool to interpret the time course of virological markers
(e.g. viral load) during HIV treatment [27–31] and contributes
much to our current understanding of the in vivo dynamics of HIV.
Sedaghat et al. [32,33] used a mathematical modelling approach
to analyze the rapid decay of plasma viral load after application of
integrase inhibitors. They infer that this characteristic viral decay
is a result of the inhibited stage within the viral life cycle rather
than superior in vivo potency.
Consequently, viral load decay may be misleading for assessing
the potency of integrase inhibitors (and other novel inhibitors) in
comparison to existing drug classes. However, an alternative, more
appropriate measure of drug efficacy, which allows to directly
compare drugs from different drug classes is still missing.
PLoS Computational Biology | www.ploscompbiol.org 1 March 2010 | Volume 6 | Issue 3 | e1000720The objectives of this article are (i) to develop a novel, generic
measure of drug potency that facilitates comparison across
different drug classes; (ii) to develop a novel mathematical model
of the viral replication cycle that incorporates the action of
established and novel drugs in a mechanistic way; and (iii) to analyze
determinants of drug efficacy critical for drug discovery and
development. The proposed measure of drug efficacy, termed
reproductive capacity, extends the established in vivo marker,
plasma viral load, by incorporating additional infectious viral
stages, and the in vitro phenotypic/single-round infectivity assays
by taking into account host specific defense mechanisms. This
enables us to understand the observed discrepancies between
in vitro and in vivo efficacy for integrase inhibitors, and to elucidate
and quantify the role of immune-system related clearance
mechanisms in drug action. The results presented herein are of
particular value to categorize different molecular targets in the
HIV life cycle and are expected to be of significance for guiding
future HIV drug discovery and development.
Results
Development of a detailed model of viral life cycle and
action of anti-retroviral drugs
We derived a detailed virus-target cell interaction model as
depicted in Fig. 1. The model incorporates the mechanisms of
action of all currently approved drugs and some drugs in late
clinical development.
Target cells are produced by the immune system with some
constant rate lT.A ni n f e c t i o u sv i r u sVI reversiblybinds(witheffective
rate constants kon and koff)t oat a r g e tc e l lTU,f o r m i n gac o m p l e x
VI : TU. After binding, the virus irreversibly fuses (with rate constant
kfus) with the target cell and the viral capsid containing the viral
genomic RNA is released; this state is denoted by TRNA.D u r i n g
reverse transcription (with effective rate constant krev), genomic viral
RNA is irreversibly transformed into a more stableDNA. Viral DNA
andviralproteins form the pre-integrationcomplex(PIC),denoted by
T1. In the next step, viral DNA of the PIC is irreversibly integrated
into the DNA of the target cell (with rate constant kT), forming the
provirus T2. After integration, the infected cell cannot return to
an uninfected stage. From the proviral DNA, viral proteins are
amplified and new viruses are released (with effective rate constant
b N NT½1=(cells:day) ). Only a given percentage pw0 of the released
viruses are correctly assembled immature viruses VIM,w h i l et h e
remaining percentage (1{p) are defective virions VD that might e.g.
lack the (gag-pol-polyprotein contained) enzymes. During the final
step, the viral protease, which is packed into the correctly assembled,
immature virions VIM, is responsible for the maturation of the virus.
Author Summary
To guide drug discovery and development, measures of
drug efficacy that are linked to clinical outcome are of key
importance. In HIV treatment, decay of plasma viral load is
typically used as an in vivo measure of drug efficacy,
whereas phenotypic assays are used to assess drug efficacy
in vitro. The recent development of novel HIV drugs
resulted in a huge discrepancy between viral load decay
and in vitro predictions of drug efficacy. We used a
mathematical modelling approach to resolve this discrep-
ancy by introducing a new quantity, the reproductive
capacity, that allows a transfer of the in vitro drug efficacy
measure into the in vivo context, enabling a direct
comparison. We developed a novel model of viral
dynamics that incorporates the mechanism of action of
all established and novel antivirals. Based on the model,
we analyzed the ability of the viral infection to replicate
under different drug treatments, and estimated class-
specific times until virological failure. We conclude that the
half life of the targeted viral stage is an important class-
specific attribute that impacts on the overall success of a
drug in vivo. Our findings have direct implication for the
drug discovery and development process.
Figure 1. Detailed structural model of the viral life cycle and the mechanisms of action of different anti-retroviral drug classes.
doi:10.1371/journal.pcbi.1000720.g001
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the highly ordered cascade of cleavages, governed by differences in
the inherent processing rates at each cleavage site [34,35]. Weassume
that a fraction (1{q) of the released virus matures abnormally,
contributing to the pool of defective virions VD. Successful
maturation eventually leads to new infectious virus particles VI (with
rate constant kmat and probability q).
Depending on the stage of the life cycle, the host organism has
different abilities to clear the virus. It was assumed that infectious,
immature and defective virions VI, VIM,a n dVD, respectively, are
cleared with rate constant CL by the host. The uninfected target
cells TU,t h eTRNA stage and the early infected stage T1 are
assumed to be cleared with rate constant dT, since none of these
stages express viral proteins, while the virus-producing late infected
cell T2 is assumed to be cleared with rate constant dT2&dT.I n
addition to cell death, the target cell may fend-off the viral infection
by degrading the viral RNA or parts of the PIC, rendering the cell
uninfected. RNA is very unstable with a half life ranging from
seconds to a maximum of two hours [36,37]. Therefore, through
degradation or, e.g., by hypermutation through APOBEC3G [38],
the viral RNA can be cleared with rate constant dRNA. The cell
might also destroy essential components of the PIC (with rate
constant dPIC,T) to clear the virus.
The system of ordinary differential equations (ODEs) describing
the rate of change of the different viral species and target cells in
the detailed model (depicted in Fig. 1) is given in Supplementary
Text S1, Eqs. (S1)–(S8). As typically done in kinetic studies,
complex aspects of the viral dynamics are subsumed by ‘lumped’
parameters in the model. For instance, the rate constant of the
reverse transcription krev contains all the steps necessary to
transform the viral RNA into a double stranded DNA. The
mechanisms of action of the seven drug classes are based on
interfering with the viral life cycle at different stages. We assumed
that the effect of a drug on the targeted process is specified by
some parameter e(t)[½0,1 , i.e.,
(1{e)~
1
1z
C
IC50
   n
0
B B @
1
C C A (conc: dependent efficacy), ð1Þ
assuming some underlying averaged drug concentration C~b C C,
see [39], some fifty percent inhibitory concentration IC50, and
some drug specific Hill coefficient n, see [14]. For the purpose of
the study, this rough approximation is sufficient, however, it is
possible to also use time-varying drug concentration C~C(t)
resulting from some pharmacokinetic model, or to use more
mechanistic effects models [40,41].
The actions of the different drug classes within the viral life cycle
are shown in Fig. 1. CCR5 antagonists inhibit the association of
HIV with the CCR5 receptor in CCR5-tropic virus. They thus
affect the association constant kon. Fusion inhibitors (FI) inhibit the
process of HIV fusion, affecting kfus. Activated nucleoside reverse
transcriptase inhibitors (NRTI) compete with endogenous deox-
ynucleoside triphosphates for prolongation of the growing DNA
chain, while non-nucleoside reverse transcriptase inhibitors
(NNRTI) allosterically inhibit the function of the reverse transcrip-
tase. The effects of both drug classes result in a reduced rate at
which the RNA is reversely transcribed into DNA. Integration
inhibitors affect the integration of viral DNA into the host genome
catalytically [42–45]. In the proposed model, this alters the
transition rate constant kT from early infected cells T1 to the late
infected cells T2. Protease inhibitors (PI) bind to the catalytic pocket
of the viral protease enzyme, which is responsible for the processing
of the viral precursor polyproteins and thus the maturation of viral
particles. In the proposed model (Fig. 1), PIs therefore inhibit
maturation by decreasing the maturationconstant kmat. Maturation
inhibitors (MI) bind to the substrate of the viral protease (Gag-
polyprotein)[46] ata specific site.This bindingperturbstheordered
sequence of cleavages that is necessary for proper maturation
[47,48], resulting in defective virus morphology [49]. In the
proposed model (Fig. 1), MIs therefore decrease the probability q
that immature virus matures normally, increasing the proportion of
abnormally matured, defective viruses VD.
Impact of antiviral drugs on relative abundance of
infectious viral stages
We used the detailed virus-target cell interaction model to
predict the effect of the different drug classes on the distinct stages
of the viral life cycle. In order to enable a direct comparison
between the different drug classes, we artificially eliminated the
feedback by keeping the uninfected target cell TU and the
infective virions VI that ‘enter’ the infection cycle constant (the two
leftmost species in Fig. 1), resulting in ‘downstream’ quasi-steady
state numbers T1,ss, T2,ss, VIM,ss, VI,ss, and VD,ss. For a given drug
class and inhibition of the targeted molecular process e, the effect
of the drug on the life cycle was quantified by the four ratios
T1,ss
TU0
,
T2,ss
T1ss
,
VI,ss
VIM,ss
,
VI,ss
VD,ss
ð2Þ
as shown in Fig. 2. As expected, the drugs perturb the ratios of
viral states that encompass their site of action within the viral life
cycle. In the present example, all states that lie downstream of the
drugs’ target site are affected, while the states that lie upstream are
usually not affected. The exception are InIs, which increase the
abundance of the preceding stage T1 (Fig. 2A), while decreasing
the number of the subsequent infectious stage T2 (Fig. 2B).
Interestingly, the effect on the ratios is not always a linear function
of drug efficacy. PIs and MIs also show a different behavior
(Fig. 2D): PIs affect the ratio of infectious-to-defective virions by
decreasing the maturation rate kmat, which lowers the number of
infective virions VI, but also lowers the number of virions that
mature abnormally (contributing to VD). MIs increase the
proportion of virus that matures abnormally and decrease the
proportion of virus that matures normally, thus decreasing VI and
increasing VD, without affecting kmat.
Development of a simplified two stage virus dynamics
model
The detailed model (Fig. 1) contains parameters that are difficult
to measure and currently not available. We therefore reduced the
detailed model based on reasonable quasi-steady state assumptions
to obtain a simplified model of virus-target cell interaction
dynamics that is parameterizable in terms of established and
validated parameter values (see Supplementary Text S1). In
particular, we have eliminated the intermediate stages of the cell-
virus complex TU : VI, the infected cells prior to reverse
transcription TRNA and the immature virus VIM in the original
model (Fig. 1). As a consequence, we derived a lumped infection
rate constant b, which describes the infection of a susceptible cell
towards the stage, where the viral RNA has been successfully
transformed into DNA. We also derived a virus clearance CLT
that is associated with the loss of virus during the intermediate
stages before reverse transcription and the release rate constant of
infectious virus N.
Drug-Class Specific Impact on HIV
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b~
kfus
KD
:rrev,w, ð3Þ
where kfus denotes the fusion rate constant, KD the dissociation con-
stant of the virus-target cell complex, and rrev,w denotes the probability
that reverse transcription is successfully completed (see Supplementary
Text S1). The lumped virus clearance (loss of virus by, e.g., genome
destruction) in the intermediate stages is given by the parameter
CLT~
1
rrev,w
{1
 !
:b: ð4Þ
The number of released, infectious viruses is given by
N~q:p:rPR,w:b N N, ð5Þ
where p and q are the probabilities that the released virus is correctly
assembledandmaturesnormally,andrPR,w isthe probability that the
released virus matures before being cleared by the immune system
(see Supplementary Text S1). The lumped model can be parame-
terized in terms of six unknown parameters (b,b N N,lT,dT,dT2,CL),
which equals the number of estimated parameters using standard
models [28]. For the remaining parameters, we have provided values
from the literature (see Supplementary Text S1).
In the following, we considered two types of target cells (T-Cells
and a longerlived cellpopulation,which we refer to asmacrophages)
and finally incorporated the viral mutation process (resulting from
erroneous reverse transcription) into the overall model. Whether the
longer lived cell population consists solely of macrophages in vivo
remains unknown. There is, however, some evidence that the kinetic
characteristics of the longer lived cell population are similar to those
of the macrophage population [33]. The proposed simplified two-
stage virus dynamics model is shown in Fig. 3. It comprises T-cells,
macrophages, free non-infectious virus (TU,MU,VNI, respectively),
free infectious virus of mutant strain i,VI(i), and four types of
infected cells belonging to mutant strain i: infected T-cells and
macrophages prior to proviral genomic integration (T1(i) and M1(i),
respectively) and infected T-cells and macrophages after proviral
genomic integration (T2(i) and M2(i), respectively). The rates of
Figure 2. Mechanistic effects of drug classes on viral infective compartments. Ratios are affected through treatment with different drug
classes. Predictions are based on the detailed model (see Fig. 1) and mechanistic effect e varying from 0–1. Chosen parameter values:
CL~23, dT~0:02, dT2~1, kT~0:35, dPIC,T~0:35, dRNA~1440, koff~106, rfusion~1440, rRT~48, rmat~12 in ½1=day ; N~1000 in ½1=(cells:day) ;
l~2:109 in ½cells=day ;KD~1000 in ½cells  and q~p~0:99 (unit less):
doi:10.1371/journal.pcbi.1000720.g002
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are given by the following system of ODEs:
d
dt
TU~lTzdPIC,T:T1(i){dT:TU{
X
i
bT(i):V(i):TU
d
dt
MU~lMzdPIC,M:M1(i){dM:MU{
X
i
bM(i):V(i):MU
d
dt
T1(i)~bT(i):V(i):TU{(dT1zdPIC,TzkT(i)):T1(i)
d
dt
M1(i)~bM(i):V(i):MU{(dM1zdPIC,MzkM(i)):M1(i)
d
dt
T2(i)~
X
k
kT(k)T1(k):pk?i{dT2
:T2(i)
d
dt
M2(i)~
X
k
kM(k)M1(k):pk?i{dM2
:M2(i)
d
dt
VI(i)~NM(i):M2(i)zNT(i):T2(i)
{½CLz(CLT(i)zbT(i))TUz(CLM(i)zbM(i))MU :V(i)
d
dt
VNI~
X
i
½(b N NT(i){NT(i))T2(i)z(b N NM(i){NM(i))M2(i) {CL:VNI,
ð6Þ
where lT and lM are the birth rates of uninfected T-cells and
macrophages, and dT and dM are their death rate constants. The
parameters kT(k) and kM(k) are the integration rate constants of
mutant strain k. The parameters dT1,dT2,dM1 and dM2 are the
death rate constants of T1,T2,M1 and M2 cells. The parameters
dPIC,T and dPIC,M refer to the intracellular degradation of essential
components of the pre-integration complex, e.g., by the host cell
proteasome within early infected T-cells and macrophages respec-
tively. b N NT(i) and b N NM(i) denote the total number of released
infectious and non-infectious virus from late infected T-cells and
macrophagesofmutantstraini and NT(i) and NM(i) arethe ratesof
release of infective virus (see Eq (5)). The parameters CLT(i) and
CLM(i) denote the clearance of mutant virus i through unsuccessful
infection of T-cells and macrophages respectively (see Eq. (4)) and
the parameters bT(i) and bM(i) denote the successful infection rate
constants of mutant virus i for T-cells and macrophages respectively.
The parameter pk?i denotes the probability to mutate from strain k
to strain i (to be defined below).
The model enabled us to mechanistically incorporate the action
of all drugs that are approved or in late clinical trial. The impact of
a compound on a corresponding (lumped) parameter in the model
is specified by g:
Figure 3. Simplified two stage virus dynamics model. Species (red cycles), reactions (black arrows), drugs and their interference in the life cycle
of HIV (blue dashed box). Target cells (TU,MU) can become successfully infected by infective virus VI with lumped infection rate constants bT and
bM, respectively, creating early infected cells T1 and M1. Infection can also be unsuccessful after the irreversible step of fusion (rate constant CLT
and CLM), eliminating the virus and rendering the cell uninfected. Early infected cells T1 and M1 can destroy essential viral proteins or DNA prior to
integration with rate constants dPIC,T and dPIC,M returning the cell to an uninfected stage. The genomic viral DNA can become integrated with rate
constants kT and kM creating late infected cells T2 and M2, which can release new infectious- and non infectious virus VI and VNI with rate
constants NT, c NT NT{NT
  
and NM, d NM NM{NM
  
, respectively. Phenotypic mutation occurs at the stage of viral genomic integration kT,kM (see
section ‘Development of a simplified two stage virus dynamics model’). All cellular compartments x can get destroyed by the immune system with
respective rate constants dx and the free virus gets cleared with rate constant CL.
doi:10.1371/journal.pcbi.1000720.g003
ð6Þ
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CLT,(CCR5,FI,RTI)~(1{gCCR5):(1{gFI): 1
rrev,w
{(1{gRTI)
 !
:bTð8Þ
kT,(InI)~(1{gInI):kT ð9Þ
NT,(PI,MI)~(1{gMI):(1{gPI(rPR,w)):NT: ð10Þ
The same quantities are defined for macrophages by replacing
the subscript T by M; see Supplementary Text S1 for details. The
overall viral dynamics model comprises a complete mutagenic
graph. In HIV infection, genomic mutation occurs during the
reverse transcription process [50]. The reverse transcriptase of
HIV lacks a proof reading mechanism in contrast to host
polymerase enzymatic reactions. However, viral proteins from
newly mutated viral genomes are only produced after integration
of the viral genome into the host cell DNA. The proteins required
for the stable integration of the newly mutated viral genome
originate from the founder virus. Therefore, phenotypically, drug
resistance of new mutants will only be observed after integration,
i.e., in the infectious stages T2 and M2. In total, the model includes
2L different viral strains i that contain point mutations in any
pattern of the modelled L possible mutations. For two distinct
mutations L~2, the mutagenic graph is shown in Fig. 4A. Each
mutant i can mutate into every other mutant k in one step. The
probability pk?i to mutate from a strain k into another strain i can
be directly derived from the mutagenic pathways in Fig. 4A, i.e.,
pk?i~mh(i,k):(1{m)
L{h(i,k), ð11Þ
where m denotes the mutation probability per base and reverse
transcription process (m&2:16:10{5 [50]), h(i,k) denotes the
hamming distance between strain k and strain i, and L is the total
number of different positions that are considered in our model.
The phenotype of each mutant strain i is modelled by introducing
a selective disadvantage s(i), which denotes the loss of functionality
(e.g., in the activity of some viral enzyme that is affected by the
mutation) relative to the wild type, and a strain specific inhibitory
activity (g(i,j)) of treatment j against the mutant strain i. For
example, the strain specific infection rate i under a certain
treatment j is given by b(i,j)~(1{g(i,j)):(1{s(i)):b(wt,w), where
b(wt,w) denotes the infection rate constant of the wild type wt in
the absence of drug w (given in Table 1). Since some viral strains
are present only in very low copy numbers, we used a hybrid
stochastic deterministic approach [51] to model the overall virus
dynamics model (see Materials and Methods section for details).
Reproductive capacity for predicting drug–specific
impact on viral replication
The production of infectious offspring is crucial for the survival of
a viral population. The phenotypic single-round infectivity assay
measures the amount of infectious offspring after one round of
replication. For a given drug, the assay quantifies the drug’s efficacy
by measuring the reduction in viral offspring relative to the drug-
free situation. We defined a new quantity—termed the reproductive
capacity Rcap—, which transfers the principle of the phenotypic
single-round infectivity assay into a mathematical term. Its
definition involves the quasi-species distribution and the basic
reproductive numbers of all pathogenic sub-stages. The reproduc-
tive capacity characterizes the fitness of a given state of the infection
from the perspective of a potential treatment j by quantifying the
expected total number of offspring under the treatment j.
The basic reproductive number R0 is a well characterized
quantity in epidemiology that denotes the expected number of
Figure 4. Fitness and possible mutational pathways. A: General transition pathways between wild type (00) and a fully drug resistant strain
(11) that involves two partly-resistant intermediates (10,01). B: Fitness in the presence of a drug. C: Fitness in the absence of drugs. Dashed line:
critical fitness that allows the strain to survive, i.e, R0(i)w1.
doi:10.1371/journal.pcbi.1000720.g004
Table 1. Model parameters generally used in simulations.
Parameter Value Reference Parameter Value Reference
lT 2:109 [57] lM 6:9:107 [33]
bT 8:10{12 [32] bM 1:10{14 }
b N NT 1000 [33] b N NM 100 [33]
dT,dT1 0.02 [33] dM,dM1 0.0069 [33]
dT2 1[ 7 3 ] dM2 0.09 }
CL 23 [73] p:q:rPR,w 0.67 {
rrev,w 0.33 [74,75] m 2:16:10{5 [50]
kT 0.35 [75] kM 0.07 }
dPIC,T 0.35 [75,76] dPIC,M 0.0035 }
kmat 12 [34] - - -
All parameters in units [1/day], except p:q:rPR,w (unit less) and m in
½1=(rev:trans::base) . } parameters chosen to reproduce clinical data. { chosen
according to the assumption that p~q~1 and utilizing parameters kmat and
CL to determine rPR,w~kmat=(kmatzCL)~0:67.
doi:10.1371/journal.pcbi.1000720.t001
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R0w1 then the infection will spread, while for R0v1 the infection
will die out. The strain associated reproductive number R0(i,j)
characterizes the fitness of a viral strain i in a pharmacologically
modified environment, specified by a drug treatment j. We used
the ‘survival function’ approach [53] to calculate the reproductive
numbers for mutant strains i under treatment j. In our context, the
survival function is of particular value, since it captures the
possible event of mutation for all infective classes.
Based on the two-stage virus dynamics model, the basic
reproductive number RV(i,j) of a single virus of strain i under
treatment j is given by
RV(i,j)~
bT(i,j)TU:kT(i,j):NT(i,j)
ru(i,j):rT(i,j):dT2
z
bM(i,j)MU:kM(i,j):NM(i,j)
ru(i,j):rM(i,j):dM2
ð12Þ
with constants
ru(i,j)~CLzCLT(i,j)zbT(i,j) ½  TUzCLM(i,j)zbM(i,j) ½  MUð13Þ
rT(i,j)~dTzdPIC,TzkT(i,j) ð14Þ
rM(i,j)~dMzdPIC,MzkM(i,j): ð15Þ
Since infected cells are also pathogens, which can lead to a
rebound of the disease even in the absence of any virus, we also
determined their basic reproductive numbers under a given
treatment j. The basic reproductive numbers RT1(i,j) and
RM1(i,j) of the infectious stages T1 and M1, associated with the
viral strain i, are given by
RT1(i,j)~
kT(i,j):NT(i,j)
rT(i,j):dT2
:bT(i,j)TUzbM(i,j)MU
ru(i,j)
ð16Þ
RM1(i,j)~
kM(i,j):NM(i,j)
rM(i,j):dM2
:bT(i,j)TUzbM(i,j)MU
ru(i,j)
: ð17Þ
Finally, the reproductive numbers RT2(i,j) and RM2(i,j) of the infec-
tious stages T2 and M2, associated with the viral strain i,a r eg i v e nb y
RT2(i,j)~
NT(i,j)
dT2
: kT(i,j)TU:bT(i,j)
ru(i,j):rT(i,j)
z
kM(i,j)MU:bM(i,j)
ru(i,j):rM(i,j)
  
ð18Þ
RM2(i,j)~
NM(i,j)
dM2
: kT(i,j)TU:bT(i,j)
ru(i,j):rT(i,j)
z
kM(i,j)MU:bM(i,j)
ru(i,j):rM(i,j)
  
: ð19Þ
We defined the reproductive capacity Rcap(j) of the entire quasi-
species ensemble under treatment j as the weighted sum of the basic
reproductive numbers of all pathogenic stages of mutant strain i,
i.e., free virus, infected T-cells and infected macrophages, where the
weights are the abundance of the corresponding pathogenic stage:
Rcap(j)~
X
i
½VI(i)RV(i,j)zT1(i)RT1(i,j)zM1(i)RM1(i,j)
zT2(i)RT2(i,j)zM2(i)RM2(i,j) :
ð20Þ
The reproductive capacity Rcap(j) can be interpreted as the
expected total number of infectious offspring that the infection
produces in one round of replication under a certain treatment j,
given the current state of the infection.
Relation to viral load and phenotypic/single-round
infectivity assay. The viral load considers the total
concentration of free virus, consisting of non-infectious virus VNI
and infectious virus VI(i), belonging to all mutant strains i.I n
contrast to the reproductive capacity, viral load does not assess the
ability of distinct viral strains i to replicate (in terms of RV). In
mathematical terms, the viral load is given by
Vload~
X
i
VI(i)zVNI: ð21Þ
The in vitro reproductive capacity, corresponding to the read-out of
the phenotypic assay RpA(j) (under treatment j) is conceptionally
similar to Eq. (20). However, in comparison to the above defined in
vivo measure, the in vitro measure would not take into account: (i)
the clearance of any infective stage by the immune system (relating
to the parameters CL,CLT(i,j),CLM(i,j),dT,dM,dT2, and dM2),
and (ii) the abundance of the different infected cell types (e.g., T-
cells and macrophages). The assay measures one round of
replication, denoted by ^ R R^ T T2, starting from a late stage infected
cell ^ T T2. Mathematically expressed, the primary output is given by
RpA(j)~
X
i
^ T T2(i):^ R R^ T T2(i,j): ð22Þ
Drug-class specific decay of viral load and reproductive
capacity
Application of drugs/drug classes changes the total size and the
composition of the viral population. The impact of this change is
typically evaluated in terms of the decay of the viral load over
time. We used the reproductive capacity Rcap(j) to also evaluate
viral replication under various hypothetical treatments j. In Fig. 5,
we predicted the impact of the different drug classes on the decay
of the plasma viral load and the reproductive capacity Rcap(w), i.e.,
the fitness of the whole virus population, evaluated in the absence
of drugs. As typically done, we assumed 100% drug efficacy g.
In terms of the plasma viral load decay (Fig. 5A), we observe a
faster initial decay for InIs in comparison to all other compound
classes, in agreement with clinical data [21] and theoretical
analysis [32,33]. The onset of viral load decay is delayed for all
other compound classes as observed clinically [12,27], see also
Figure S1. In agreement with clinical data [21], in the case of InI
treatment, the second phase of viral decay starts earlier after
treatment initiation and exhibits &70% less viremia in compar-
ison to other drug classes, but shows the same decay. Notably, the
change of the ratio of infective virus-to-total virus (see Fig. 5, inset)
upon PI or MI administration is not reflected by the total viral
decay in the blood plasma.
Most noticeable, the reproductive capacity (Fig. 5B) discrimi-
nates between RTIs, FIs and CCR5-antagonists vs. InI vs. PIs and
MIs. It can be seen, that protease and maturation inhibitors
reduce Rcap most efficiently initially and shift it to an overall lower
level. Integrase inhibitors cause a slightly faster initial decay in
Rcap, in comparison to RTIs, FIs and CCR5-antagonists, which
consistent with the rapid decay in viral load (Fig. 5A). However, in
contrast to viral load decay, the initial fast decay of Rcap levels off
and the second phase decay is flatter for InIs in comparison to
ð12Þ
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NNRTIs, CCR5 inhibitors and FIs on Rcap is comparable
(Fig. 5B). Remarkably, these inhibitors induce an initial increase
in Rcap (see next section for details), followed by a slow first phase
decay, followed by a second phase decay that is parallel to the
decay of Rcap in the case of PI- and MI-treatment, sustaining
overall higher levels of Rcap in comparison to PIs and MIs. In the
next section, we further elucidate the reasons for these class-
specific differences.
Immune-system related clearance is critical determinant
of drug-class specific decay
In view of the analysis performed in Fig. 5B, Rcap is
directly correlated to the overall abundance of viral infectives
(VI,T1,T2,M1,M2).
PIs and MIs primarily act on infectious virus VI (see Fig. 5, inset),
by reducing the proportionality factor (NT=CL and NM=CL)t h a t
determines the abundance of infectious virus in the first- and second
phase decay (see Eq. (10)). The infectious virus VI is rapidly cleared
bythe immune system[54].Therefore, applicationofhighlyefficient
PIs and MIs leads to a rapid reduction of infectious virus VI,a s
illustratedinFig.6DandFig.5(inset).Thisreductionisalsoreflected
by the initial drop of Rcap in Fig. 5B. In the case of PI and MI
treatment, infected T-cells are quickly becoming the most abundant
infectious compartment (Fig. 6D) and subsequently dominate the
decay characteristics of Rcap in Fig. 5B. In the final phase, late
infected macrophages (M2) are becoming the most abundant
compartmentandthusdominatethedecayofRcap inthefinalphase.
Integrase inhibitors prevent the integration of the viral genome
and thuspreventthetransition of earlyinfectedcells (pre-integration,
T1 and M1) to late infected cells (post-integration, T2 and M2), see
Fig. 3. By inhibiting the transition from early to late infectious cells,
integrase inhibitors increase the decay of late infected T2-cells (see
Fig. 6C). In the case of InI treatment, infectious virus VI is initially
proportional to T2, explaining the observed more rapid first-phase
decline in Rcap in Fig. 5B. However, blocking the transition from T1
to T2 can also slow the decay of the T1-compartment, which might
become more abundant than VI after the initial decay. In the final
phase both T1 and VI become proportional to- and remain more
abundant than M2, which explains the overall higher levels of Rcap
in the final phase (see Fig. 5B).
The effects of NRTIs, NNRTIs, CCR5 inhibitors and FIs on
Rcap are comparable (Fig. 5B), as they primarily act on pre-
integrative early infected cells (T1 and M1). The difference between
entry inhibitors and reverse transcriptase inhibitors is marginal,
because the clearance of virus by infection is negligible compared to
theclearancebytheimmunesystem(CLTvCL andCLMvCL).A
positive result of entry inhibitors (FI/CCR5) and RTIs (NRTIs/
NNRTIs) is an increased number of uninfected cells, which also
results in an initial increase in the reproductive capacity Rcap (see
Fig. 5B). During treatment with NRTIs, NNRTIs, CCR5 inhibitors
and FIs, infective virus VI is the most abundant compartment. The
decay in the first phase is proportional to the decay of the late
infected cells, T2. Once the abundance of T2 falls below M2,t h e
decay of VI and thus Rcap in Fig. 5B is proportional to the decay of
late infected macrophages M2.
The pattern of virological removal influences the time to
virological rebound after treatment application
In the following, we predict how the distinct viral dynamics after
drug application affect drug efficacy in vivo. The long-term in vivo
efficacy of an antiviral drug depends on many different factors,
Figure 5. Decay of viral load and reproductive capacity after treatment initiation. A: Plasma virus load decay after treatment initiation.
Integrase inhibitors (InI) produce a faster decay of virus load than all other compound classes. Red solid-, black dotted-, green dash-dotted- and blue
dashed lines indicate simulation results with different inhibitor classes and parameters from Table 1. Black diamonds indicate median viral load data
from [27] (PI monotherapy), numerically available in [70]. Black squares and black bullets indicate median viral load data from [21] (NRTI + background
therapy and InI+background therapy, respectively). The horizontal dashed black line indicates the limit of detection of current assays (50 copies of
HIV RNA per mL). Inset: Protease- and maturation inhibitors (PI and MI) change the ratio of infectious to total virus (VI : Vtot). B: The evolution of the
reproductive capacity (evaluated at the drug free state Rcap(w)) after treatment with different drug classes. Model parameters are as indicated in
Table 1. The initial infection was assumed to consist of wild type only. Drug efficacy g was assumed to be 100%. Total body virus has been converted
to plasma viral load by assuming that the virus distributes into the plasma (Vplas:~3:1 liters, which surrounds 2% of infected cells) and the interstitial
space (Vint:~9:6 liters [71], which surrounds 98% of infected cells). The volume of distribution with reference to the plasma concentration has been
calculated using the well-known formula vol. distr ~Kint::plas::Vint:zVplas:, see e.g. [72], where Kint::plas:~98%=2%~50. Finally, we assume that on
average each virus contains 2 viral RNAs (which are measured [viral RNA/mL] plasma).
doi:10.1371/journal.pcbi.1000720.g005
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challenge by developing resistance mutations. The ability to
develop drug resistance is strongly dependent on the induced
pattern of resistance mutations against a particular drug, but also
on the velocity at which replication competent compartments
(VI,T1,T2,M1,M2) are removed from the body. Since anti-
retroviral drug classes target different stages in the viral life cycle,
they are likely to induce different patterns by which viral
compartments are removed from the body (see Fig. 6) and might
therefore exhibit different long-term in vivo efficacies.
To illustrate the sole impact of virological removal
(VI,T1,T2,M1,M2) on resistance development and therefore on
drug efficacy, we have intentionally chosen a simplistic, unified
mutational landscape and considered the time to viral rebound as
a long-term measure of efficacy. We denoted virological rebound,
if the viral load reaches 90% of the pre-treatment viral load. We
assumed that the drugs inhibited their targeted (lumped)
parameter (see Eqs. (7)–(10)) by 90% in the wild type (g~0:9),
by 45% in a one-mutation strain (g~0:45) and are entirely
inefficient in the double-mutant (g~0). Drug-specific and more
realistic mutational landscapes are possible, but in view of the
current analysis (elucidating the impact of class-specific virological
removal), they would blur the results.
In Table 2, the time to virological rebound for the different drug
classes based on the above simplistic mutation model is reported.
The virus generally rebounds to 90% of pre-treatment levels after
1–2 month of monotherapy, which is in the same order of
magnitude as clinically observed rebound times [55–57]. Although
inhibition g was assumed to be identical across all drug classes, the
Figure 6. Decay of infective compartments after initiation of drug treatment. A: Decay of infective compartments after treatment with FI
and CCR5-antagonists. B: Decay of infective compartments after treatment with NRTIs and NNRTIs. C: Decay of infective compartments after
treatment with InIs. D: Decay of infective compartments after treatment with PIs.
doi:10.1371/journal.pcbi.1000720.g006
Table 2. Virological rebound times resulting from distinct
virological removal.
Drug/Selec.
Disadvantage 30% 25% 20% 15% 10% 5% 1%
InI 48.13 44.44 41.33 38.70 36.43 34.65 33.25
FI/CCR5-antag. 53.71 47.81 43.09 39.57 36.47 33.77 32.06
NRTI/NNRTI 55.51 48.76 43.86 39.99 36.61 33.94 32.11
PI/MI 55.28 49.03 43.74 39.84 36.66 33.95 32.15
The time to virological rebound depends on both the cost of resistance
(‘selective disadvantage’, s) and the choice of drugs. Each table entry shows the
time to virological rebound in [days] in an ensemble of 1000 hybrid stochastic
deterministic simulations, where we assumed that the efficacy of the drugs
against the wild type was 90%. The drug was 45% effective against an one-
mutation strain and completely inefficient against the double-mutant. The
fraction of non-infectious viruses (1{p:q:rPR,w) was set to one-third and the
initial population was assumed to be all wild type. The viral load was said to be
rebounded, if the viral load reached 90% of the pre-treatment viral load.
doi:10.1371/journal.pcbi.1000720.t002
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resistance confers a marked loss in fitness (i.e. selective disadvan-
tage=30%), PIs show the longest time to virologically rebound,
and the InIs the shortest.
For integrase inhibitors, the difference between the decay of
plasma viral load and their predicted long-term efficacy is quite
pronounced. Their comparably shorter times to virological
rebound are in strong contrast to their steep initial decrease of
plasma viral load (see Fig. 5A), but consistent with the decay
pattern of the reproductive capacity (Fig. 5B). For the EIs, RTIs,
PIs and MIs, the predicted time to virological rebound is also
much more consistent with the decay characteristics of the
reproductive capacity (Fig. 5B) than with the decay pattern of
total viral load (see Fig. 5A).
Discussion
In clinical studies, the first approved integrase inhibitor,
raltegravir, induced an extremely rapid decline in viral load when
applied both as monotherapy [10] and in combination with an
optimized NRTI background therapy [21–24]. While it was
initially speculated that the observed decline might be a result of
superior potency of raltegravir, it is now emerging that the viral
decline in InI-based therapy could be a class-specific phenomenon
[25,26]. Moreover, superior potency of InIs (in terms of g) was not
confirmed by single-round infectivity assays [14]. The mechanisms
underlying the decay dynamics are still not clear [58] and
controversially discussed [21,32].
In [32], a two stage model of the viral replication cycleis presented,
which explains the differences between the decay of viral load
between RTIs and InIs based on the stage at which the drugs affect
the dynamics of viral replication. The model explicitly distinguishes
two viral stages, early-stage infected cells and late-stage infected target
cells, which are specifically defined for a pair of drugs under
examination. The authors further conclude that the viral dynamics
produced by drugs from different anti-retroviral classes should not be
directlycomparedtoinferdrugpotency[33].Analternativemeasure,
as it is imperative for guiding drug discovery and prioritizing drug
candidates in later development stages, is still lacking.
All currently approved antivirals exert their effect by inhibiting
the replication of HIV. The extent at which replication is
inhibited, is therefore a unifying indicator for drug efficacy across
all drug classes. Replication assays, e.g., phenotypic assays [15] or
replication capacity assays [59], analyze drug efficacy in terms of
viral replication in vitro. The replicative fitness of HIV in vivo,
however, depends on the interaction of a multitude of viral and
host factors. Replication assays represent the dynamics of HIV
under the assay conditions, which lack many host factors, in
particular the immune responses to the infection. However, since it
is particularly useful to compare compounds in terms of replication
inhibition, we adopt the dynamic approach of replication assays to
define the reproductive capacity Rcap. In silico, we are able to
consider the host response to the viral infection and can thus
extrapolate the replication approach from in vitro to in vivo. In [60],
the authors used a similar approach to compare the effect of
distinct antiviral classes utilizing age-structured models.
We derived a single detailed model of the viral replication cycle
and deduced a reduced two stage model, which incorporates the
action of all approved HIV drugs. Our two-stage model allows to
predict the action of any number of drugs simultaneously, including
common HAART cocktails, potentially belonging to different drug
classes. In contrast, in [32], the stages of the two-stage model of
viral replication are not specified a priori and have to be
determined by the two drugs that are analyzed and compared.
Based on the proposed detailed and reduced model, we identify
the following effects of currently approved drugs: EI and RTIs
decrease the infection rate and thus the number of new infections.
The impact on the release of new virus (and virus decline) is
therefore delayed by the viral life cycle. MIs and PIs do not
interfere with the total amount of virus that is being released, but
rather shift the ratio of infective to total virus, VI : Vtot (see Fig. 5,
inset), which is not directly reflected by total plasma viral load.
Since the kinetics of the free virus are rapid [54], this has an
immediate impact on the number of new infections. Subsequently,
this impact on the number of new infections affects the total viral
release (and thus total plasma virus load) in a similar manner as
EIs and RTIs, creating a ‘shoulder’ phase. Hence, we obtain
new infections~ b
z}|{
EI,RTI
:TU: VI |{z}
PI,MI
{ ?
life{cycle
total virus release:ð23Þ
In our model, EIs, RTIs, PIs and MIs produce an identical decay
of plasma viral load (see Fig. 5A), when assuming 100% inhibition,
respectively. In particular, the onset of viral load decay is similarly
delayed (‘shoulder phase’) with these inhibitors (see Figure S1), in
agreement with clinical observations [12,27]. Previously discussed
theoretical differences in the viral response between RTIs and PIs
(see Eq. (5.7) vs. Eq. (5.16) in [61]) yield similar dynamics when
more recent (higher) estimates of viral clearance are used [54].
In contrast to other inhibitor classes, InIs decrease the amount
of late infected cells (T2,M2) (see Fig. 2), which has an immediate
impact on total virus release, i.e.,
total virus release~b N N: T2 |{z}
InI
: ð24Þ
The impact of InIs on viral load decay is immediate and not
delayed by the viral replication cycle as in the case of all other
compounds [12,27]. Thus, the onset of observed total viral decay
is faster for InIs than for other compounds, irrespective of their
potency (which was set equal for all compounds in Fig. 5A).
Furthermore, the decay of viral load in the first phase is steeper for
InIs in comparison to other inhibitor classes (see Fig. 5A). The
viral load decline in the first phase is proportional to the decay of
the late infected T-cells T2 (see Fig. 6). Sedaghat et al. [32] derived
analytical solutions for the viral decay dynamics after InI and RTI
treatment (see Eqs. (9) and (10) in [32]), which demonstrate that
the viral decay after InI treatment is determined by the death rate
of late infected cells (dT2), while in the case of RTI treatment, the
decay is determined by the ‘‘flushing-out’’ of the early infected
cells (T1) and the death rate of the late infected cells dT2, leading to
overall faster viral declines in the case of InI treatment in the first
phase.
The long-term in vivo efficacy of an antiviral drug depends on
many different factors, particularly the ability of the virus to adapt
to the pharmacological challenge by developing resistance
mutations. The ability to develop drug resistance is strongly
dependent on the induced pattern of resistance mutations against a
particular drug, but might also be influenced by the velocity at
which replication competent compartments are removed from the
body. However, viral load decay focusses on only one single
variable, namely the total output of virus, whereas other infectious
stages (e.g. T1,T2,M1,M2) remain ‘hidden’. Furthermore, the ratio
of infective virus-to-total virus (VI=Vtot) is not resolved, which
might underestimate the long-term efficacy of PIs and MIs that
target this ratio (see Table 2 in relation to Fig. 5A). In the section
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virological rebound after treatment application’, we have com-
pared the impact of drug-class specific removal patterns on the
long-term efficacy of antivirals (in terms of resistance develop-
ment). We showed that although inhibition g was assumed to be
identical across all drug classes, the times to virological rebound
(used as a measure of long-term efficacy) differed, with PIs showing
the longest time to virologically rebound, and InIs the shortest.
The reproductive capacity has been monitored over time in
Fig. 5B to depict class-specific long-term efficacy of antivirals
based on the hosts’ ability to clear the targeted infectant in the
viral life cycle. The main conclusion is that the long-term efficacy
is larger for compounds that target viral life-stages that are cleared
at a fast rate. It is generally assumed that the free virus is cleared at
the fastest rate [27,54]. Since MIs and PIs reduce the production
of infective virus VI (see Fig. 2), they reduce the virus’ ability to
produce offspring faster than all other drug classes. Furthermore,
since resistance development is correlated with the extent of
replication, we infer that PIs and MIs, based on their viral target,
are the most efficient drug classes in terms of reducing the
probability of resistance development. This assumption correlates
well with the observed rebound times in Table 2 and is also
supported by the fact that the introduction of PIs marked the
success of HAART [1].
During drug discovery, the pre-clinical- and the clinical
development process, in vitro surrogate measures or in vivo drug
efficacy measures are important to prioritize drug candidates.
The mechanistic mode of action of a compound at its target site
can be elucidated by cell free assays that use purified viral protein,
e.g. reverse transcriptase for RTIs. The influence of viral
mutation, the immune system and pharmacokinetics are absent
in this type of assay. However, it is possible to deduce the
pharmacodynamic mode (e.g. Eq. (1), see also [41]) and thus the
parameter e from these types of assays, which denotes the extent of
inhibition of the molecular process by the compound. Mathemat-
ical models of HIV dynamics use a minimal number of
parameters, making them suitable for parameter fitting and
comparison with clinical data. The parameters used in the models
are often lumped, summarizing many viral processes. For
example, binding, fusion and reverse transcription are part of
the infection rate b (see Eq. (3)). Inhibition of lumped model
parameters (denoted by g) might therefore differ from inhibition of
the molecular process e, which is measured by cell-free in vitro
assays. We have provided equations (Eqs. (S24) and (S31),
Supplementary Text S1) that enable the use of pharmacodynamic
information e, derived from cell free assays (inhibition of the
targeted molecular process), in a (lumped) mathematical model of
HIV dynamics (utilizing g).
The presented model can be extended to incorporate drug-
specific escape pathways [62,63] or realistic time-varying drug
pharmacokinetics [41]. If in vivo pharmacokinetic data is available
(in terms of time-varying concentrations C(t) in Eq. (1)), then
extrapolation from in vitro to in vivo is possible and the mechanistic
understanding of drug effects, its parametrization and extrapola-
tion is facilitated. For RTIs and PIs, we found a nonlinear
relationship between e and g (see Eqs. (S24) and (S31),
Supplementary Text S1). Utilization of Eqs. (S24) and (S31)
allows to simulate drug effects based on their mechanistic
understanding in a lumped model, that can be compared with
clinical data.
The model can also be extended to include latently infected cells
(very long lived infected cells). We did not consider them in this
study, since they are expected to contribute little to the dynamics
analyzed herein (the first and the second decay phase).
The reproductive capacity is a useful concept to analyze and
monitor drug efficacy in silico. In its current form, the reproductive
capacity requires detailed knowledge about (i) the composition of
the viral population, and (ii) the fitness of the different viral strains
under a given treatment (reproductive numbers, Eqs. (12) and
(16)–(19)).
The fitness of certain viral strains can be assessed in vitro, e.g., by
phenotypic assays. We model strain specific fitness i under
treatment j, in terms of two parameters: the selective disadvantage
s(i), which denotes the loss in replication of mutant i, relative to
the wild type; and the efficacy of treatment j against mutant i in
terms of the parameter g(i,j). The selective disadvantage can, e.g.,
be estimated by performing a phenotypic assay with a certain
mutant virus i in the absence of drug and then comparing it to the
assay with the wild type. The parameter g(i,j) is already being
assessed in practice (e.g., [15]), usually in terms of a fold increase in
IC50.
Acquisition of detailed knowledge about the composition of the
viral population might, due to recent advances in sequencing
technology [64–67], become feasible in the future. However, novel
sequencing technology requires large amounts of viral RNA,
which cannot be derived when the viral load is below the limits of
detection.
Materials and Methods
Realization of hybrid simulations
The overall virus dynamics in our model comprise different viral
strains with copy numbers that can vary over several orders of
magnitude. For this reason we have chosen a hybrid (stochastic
deterministic) setting for numerical simulation. This approach (i)
takes stochastic fluctuations in the slow reaction processes into
account; and (ii) reduces the computational costs for the simulation
of the fast (deterministic) system dynamics. We used the direct
hybrid method proposed in [51]. Elementary reactions were
treated stochastically whenever their propensity function or the
quantity of at least one of their reactants was below a certain
threshold (for all numerical simulations this threshold was set to 5).
For the numerical integration of the deterministic part of the
system, we implemented a solver in C++ that is based on
numerical differentiation formulas [68] and uses strategies for
error control and step size control comparable to ode15s in Matlab
[69]. To generate the data for Table 2, we performed 1000 hybrid
simulations for each condition. With realization start (t=0), the
effects of the drug treatment were simulated until the viral
population size reached 90% of its pre-treatment value, i.e.,
virological rebound occurred. During a simulation, the stochastic
partitioning of the reaction system was dynamically updated and
stochastic reaction events were realized accordingly. Every
numerical calculation was computed with a relative error tolerance
of 10{6 and an absolute error tolerance of 10{9. The hybrid
simulations for Table 2 were performed on two Intel Quad-Core
Xeon E5345 processors with 2.33 GHz and 32 GB RAM, which
took nearly 46 hours in total or approximately 6 seconds per
simulation, respectively.
Supporting Information
Text S1 This file contains the derivation of the simplified model
(Fig. 3) from the detailed model (Fig. 1).
Found at: doi:10.1371/journal.pcbi.1000720.s001 (0.30 MB PDF)
Figure S1 Delay in the onset of viral load decay, exemplified for
PI treatment. Simulation results (red line) using the novel two stage
virus dynamics model and simulating 100% effective PI treatment
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from PI (RTV) monotherapy.
Found at: doi:10.1371/journal.pcbi.1000720.s002 (0.91 MB EPS)
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